A pilot study to determine the effects of short-term thiazolidinedione [rosiglitazone, pioglitazone] treatment on vascular risk markers in type 2 diabetes patients.
Phase of Trial: Phase IV
Latest Information Update: 11 Dec 2009
At a glance
- Drugs Pioglitazone (Primary) ; Rosiglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 11 Dec 2009 Last checked against ClinicalTrials.gov record.
- 02 Jan 2008 New trial record.